Hasil Pencarian - Sarit Assouline

  • Menampilkan 1 - 14 hasil dari 14
Perbaiki Hasil
  1. 1
    Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

    Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib oleh Anna Franceschino, Lucia Tornaghi, Valerie Benemacher, Sarit Assouline, Carlo Gambacorti-Passerini

    Diterbitkan 2008-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera

    Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera oleh Eliane Nguyen, Michaël Harnois, Lambert Busque, Shireen Sirhan, Sarit Assouline, Ines Chamaki, Harold Olney, Luigina Mollica, Natasha Szuber

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy

    Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy oleh David Sanford, Pierre Desjardins, Brian Leber, Kristjan Paulson, Sarit Assouline, Paola M. C. Lembo, Pierre-André Fournier, Heather A. Leitch

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma

    CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma oleh Raoul Santiago, Johanna Ortiz Jimenez, Reza Forghani, Nikesh Muthukrishnan, Olivier Del Corpo, Shairabi Karthigesu, Muhammad Yahya Haider, Caroline Reinhold, Sarit Assouline

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

    Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study oleh Jorge E. Cortes, Jeff H. Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H. Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

    Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized... oleh Sarit Assouline, Jadwiga Gasiorek, Julie Bergeron, Caroline Lambert, Biljana Culjkovic-Kraljacic, Eftihia Cocolakis, Chadi Zakaria, David Szlachtycz, Karen Yee, Katherine L.B. Borden

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

    A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E oleh Sarit Assouline, Biljana Culjkovic-Kraljacic, Julie Bergeron, Stephen Caplan, Eftihia Cocolakis, Caroline Lambert, Cara J. Lau, Hiba Ahmad Zahreddine, Wilson H. Miller, Katherine L. B. Borden

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity

    The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity oleh Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Audrey Emond, Filippa Pettersson, Ronald Midura, Mark Lauer, Sonia Del Rincon, Valbona Cali, Sarit Assouline, Wilson H Miller, Vincent Hascall, Katherine LB Borden

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

    Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma oleh Alexandre Benoit, Elisabeth Bou-Petit, Hsiang Chou, Melissa Lu, Cynthia Guilbert, Vincent Mingyi Luo, Sarit Assouline, Ryan D. Morin, Svetlana Dmitrienko, Roger Estrada-Tejedor, Nathalie A. Johnson, Koren K. Mann

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study

    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study oleh Christopher R. Flowers, Matthew J. Matasar, Alex F. Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný, Lisa Musick, Jamie Hirata, Annie Yang, Laurie H. Sehn

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

    S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CL... oleh Arnon Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani-Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F Seymour

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

    P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVO... oleh Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit Assouline, John Kuruvilla, Mazyar Shadman, Chan Cheah, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael Wei, Shen Yin, Iris To, Nan Hu, Juliana Min, Elicia Penuel, Anton Belousov, Alexandre Coimbra, Skander Jemaa, Brendan Bender, David Turner, L. Elizabeth Budde

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

    Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts oleh Bernhard Reis, Lori Jukofsky, Gong Chen, Giovanni Martinelli, Hua Zhong, W. Venus So, Michael J. Dickinson, Mark Drummond, Sarit Assouline, Maneja Hashemyan, Michel Theron, Steven Blotner, Je-Hwan Lee, Margaret Kasner, Sung-Soo Yoon, Ruediger Rueger, Karen Seiter, Steven A. Middleton, Kevin R. Kelly, Norbert Vey, Karen Yee, Gwen Nichols, Lin-Chi Chen, William E. Pierceall

    Diterbitkan 2016-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY

    P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY oleh Giovanni Paolo Maria Zambrotta, Sarit Assouline, Franck E. Nicolini, Elisabetta Abruzzese, Ester Pungolino, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez Larran, Ana Triguero Moreno, Alessandra Iurlo, Cristina Bucelli, Francesca Lunghi, Isabella Capodanno, Margherita Maffioli, Sara Galimberti, Giovanni Caocci, Fabio Stagno, Susanne Saussele, Carmen Fava, Philipp Le Coutre, Massimiliano Bonifacio, Veronica Guglielmana, Federica Colombo, Laura Antolinni, Carlo Gambacorti-Passerini

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: